# VKTX earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/VKTX) · [Earnings tab](https://www.lopjlb.com/stock/VKTX?tab=earnings)

Updated: 2026-10-28T05:35:30

Quarters analyzed: 8

## Cross-quarter narrative

Across 8 calls for VKTX, management tone moved from +0.70 (2024 Q1) to +0.00 (2026 Q2). Latest guidance stance: vague. Latest desk line: n/a

## Latest CallCard · Q2

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q2:** —
- **2025 Q4:** Viking Therapeutics advanced VK2735 subcutaneous and oral obesity programs into Phase III, completed VANQUISH-1 enrollment, nearing VANQUISH-2 enrollment, plans oral Phase III start in Q3 2026, maintenance study enrolled, amylin IND filing this quarter, $706M cash, CordenPharma manufacturing deal, h
- **2025 Q3:** Viking Therapeutics advances VK2735 Phase III VANQUISH obesity trials (enrollment ahead of schedule), reports positive Phase II oral data (up to 12.2% weight loss), initiates maintenance dosing study, and holds $715M cash to fund programs.
- **2025 Q2:** Viking Therapeutics reported strong cash, launched Phase III obesity trials and completed oral Phase II enrollment, but faces uncertainty around dosing, timelines and competitive landscape.
- **2024 Q4:** VKTX Q4 2024: $903M cash, net loss $110M; VK2735 SC Phase 3 start Q2 2025, oral Phase 2 underway, VK2809 NASH end-of-Phase 2 done, VK0214 X-ALD Phase 1b positive, amylin program added.
- **2024 Q3:** Viking Therapeutics reported positive Phase 2 obesity data, strong Phase 2b NASH results and encouraging early oral obesity data, while R&D spend rose and cash sits at $930M.
- **2024 Q2:** VKTX reports $942M cash, advances VK2735 obesity Phase 3 and oral Phase 2, VK2809 NASH histology success, plans end-of-Phase 2 meetings Q4 2024
- **2024 Q1:** Viking reports positive Phase II VENTURE data for subcutaneous VK2735 (up to 14.7% weight loss) and Phase I oral VK2735 (up to 5.3%), completes VOYAGE biopsies for VK2809 NASH, raises $630M to $963M cash.

## Theme arcs

- **Management tone** (deteriorating): Δ mgmt=-0.70

## Fear persistence

- **manufacturing/supply chain** [resolved]: 2024 Q1
- **competitive landscape** [recurring]: 2024 Q1, 2025 Q4
- **clinical/regulatory** [resolved]: 2024 Q1
- **intellectual property** [resolved]: 2024 Q1
- **partnership dependency** [resolved]: 2024 Q1
- **weight loss plateau uncertainty** [resolved]: 2024 Q1
- **clinical development risk** [resolved]: 2024 Q2
- **partnership risk** [recurring]: 2024 Q2, 2025 Q3
- **formulation risk** [resolved]: 2024 Q2
- **competitive risk** [recurring]: 2024 Q2, 2025 Q3

## Guidance path

2024 Q1:vague → 2024 Q2:vague → 2024 Q3:vague → 2024 Q4:vague → 2025 Q2:maintained → 2025 Q3:vague → 2025 Q4:vague → 2026 Q2:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/VKTX`